Sparks commentary - Basilea Pharmaceutica

Healthcare

Sparks - Basilea Pharmaceutica

More on this equity
misael-moreno-fN6K30xtiKE-unsplash-Basilea
Basilea (SIX: BSLN): another Cresemba milestone payment
Published by Arron Aatkar, PhD

Basilea Pharmaceutica has announced that the continued strong sales of Cresemba (isavuconazole, the copmany’s lead antifungal therapy)has triggered the second US$2.5m payment of the year. This milestone payment comes from Pfizer, based on the license agreement between the companies which covers Europe (excluding the Nordic countries) as well as China and 16 countries in the Asia Pacific Region.

Cresemba is marketed in over 70 countries. According to the latest available data, total global in-market sales of Cresemba in the 12-month period between January and December 2024 amounted to US$562m, a 19% growth year-on-year, making it the largest branded antifungal for invasive fungal infections worldwide.

Latest

Healthcare | Comment

Cereno Scientific (STO: CRNO-B) enters the FN25 Index

Industrials | Comment

AAC Clyde Space (OTCQX: AAC) share issue raising SEK64.5m

Industrials | Comment

Hercules (AIM: HERC) acquire Advantage NRG for up to £15.7m

Industrials | Comment

AVAX Group (ATH: AVAX) – Q125 results

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free